{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:26:15Z","timestamp":1763141175860},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pheochromocytoma (PCC) and paraganglioma (PGL) are rare malignancies while pathogenesis is strongly influenced by genetics. The prognostic factors of these patients remain poorly defined. We aim to study the epidemiology and survival pattern by analyzing the combination of SEER and Cancer Genome Atlas (TCGA) database. Primary outcome was overall survival (OS) and disease specific survival (DSS). Between 1973 and 2013, a total of 1014 patients with PGL or PCC were analyzed. Younger age and female were associated with better outcomes. The incidence of second primary malignancy in PGL\/PCC patients was about 14.6%. This population had a significant longer DSS. Other factors, including surgical resection and origin from of aortic\/carotid bodies, conferred remarkable survival advantage. In contrast, distant spread portended worse prognosis. Laterality, race, positive serum catecholamine marker did not demonstrate a significant association with OS and DSS. By analyzing TCGA database with total 184 patients were identified. Eighty out of 184 patients (43.5%) had at least one pathogenic mutation. Female had higher ratio of pathogenic mutations than male (58.7% vs. 41.3%) and NF1 mutation was associated with elderly population. SHDB mutation had higher percentage in male. Twenty-nine patients (15.8%) had 2 or more primary. ATRX was the most common oncogenic mutations in metastatic cohort. In conclusion, younger age, female sex, origin from aortic\/carotid bodies, complete surgical resection, regional disease, as well as concomitant second primary malignancies were associated with better prognosis. The prognostic value of radiotherapy and oncogenomics warrants further investigation.<\/jats:p>","DOI":"10.1055\/a-0851-3275","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:03:20Z","timestamp":1553731400000},"page":"451-457","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review"],"prefix":"10.1055","volume":"51","author":[{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Faber","sequence":"additional","affiliation":[{"name":"Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Celi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sosipatros","family":"Boikos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"P L Dahia","year":"2014","journal-title":"Nat. Rev Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years","volume":"102","author":"O Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"H Chen","year":"2010","journal-title":"Pancreas"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"J Crona","year":"2017","journal-title":"Endocr Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"L Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades","volume":"107","author":"P Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"457 e459","DOI":"10.1016\/j.urolonc.2017.02.006","article-title":"Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012)","volume":"35","author":"S Purnell","year":"2017","journal-title":"Urol Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjoto.2013.03.010","article-title":"Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators","volume":"34","author":"R V Sethi","year":"2013","journal-title":"Am J Otolaryngol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"J Schovanek","year":"2014","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.surg.2017.05.025","article-title":"Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery","volume":"163","author":"P Nockel","year":"2018","journal-title":"Surgery"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: A National Institute of health study","volume":"22","author":"H Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"I Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21340","article-title":"Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities","volume":"66","author":"C E DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"87","author":"O Hamidi","year":"2017","journal-title":"Clin Endocrinol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1590\/2359-3997000000299","article-title":"The clinical genetics of phaeochromocytoma and paraganglioma","volume":"61","author":"P T Kavinga Gunawardane","year":"2017","journal-title":"Arch Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"J Turchini","year":"2018","journal-title":"Histopathology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1210\/jc.2010-1588","article-title":"Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location","volume":"96","author":"G Eisenhofer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccell.2017.01.009","article-title":"Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once!","volume":"31","author":"P L Dahia","year":"2017","journal-title":"Cancer Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12022-017-9479-2","article-title":"Malignancy in pheochromocytoma or paraganglioma: integrative analysis of 176 cases in tcga","volume":"28","author":"Y J Suh","year":"2017","journal-title":"Endocrine pathology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.otohns.2010.05.031","article-title":"Clinical, histopathologic, and radiographic indicators of malignancy in head and neck paragangliomas","volume":"143","author":"D B Chapman","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005537-199901000-00007","article-title":"Malignant glomus tumors","volume":"109","author":"S Manolidis","year":"1999","journal-title":"Laryngoscope"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"H P Neumann","year":"2004","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cncr.10252","article-title":"National Cancer Data Base report on malignant paragangliomas of the head and neck","volume":"94","author":"J H Lee","year":"2002","journal-title":"Cancer"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0851-3275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T03:24:34Z","timestamp":1645759474000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0851-3275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":23,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2019,7,15]]},"published-print":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0851-3275","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]}}}